In Vitro Responsiveness of Glioma Cell Lines to Multimodality Treatment With Radiotherapy, Temozolomide, and Epidermal Growth Factor Receptor Inhibition With Cetuximab

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 3, 2007, Pages 873-882

  Combs, Stephanie E ^a   Schulz Ertner, Daniela ^a   Roth, Wilfried ^b   Herold Mende, Christel ^a   Debus, Jürgen ^a   Weber, Klaus Josef ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

EGFR; Human glioma cells; Radiation; Temozolomide; Toxicity

Indexed keywords

ANTIBODIES; BRAIN; CELL DEATH; CYTOTOXICITY; RADIATION EFFECTS; TUMORS;

CYTOTOXIC EFFECTS; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); GLIOBLASTOMA MULTIFORME (GBM) CELLS; HUMAN GLIOMA CELLS; TEMOZOLOMIDE;

RADIOTHERAPY;

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; TEMOZOLOMIDE;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG RESPONSE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; EPIDERMAL GROWTH FACTOR; GLIOBLASTOMA; HUMANS; RADIATION DOSAGE;

EID: 34249336760     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.03.002     Document Type: Article

References (58)

1. Walker M.D., Strike T.A., and Sheline G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 10 (1979) 1725-1731
2. Walker M.D., Alexander Jr. E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 (1978) 333-343
3. Combs S.E., Gutwein S., Schulz-Ertner D., et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 181 (2005) 372-377
4. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
5. Weller M., Muller B., Koch R., Bamberg M., and Krauseneck P. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21 (2003) 3276-3284
6. Bonner J.A., Harari P.M., and Giralt J.L. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of the head and neck: A phase III study of high dose radiation therapy with or without cetuximab. [Abstract]. Proc Am Soc Clin Oncol (2004)
7. Bonner J.A., De Los S.J., Waksal H.W., Needle M.N., Trummel H.Q., and Raisch K.P. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 12 (2002) 11-20
8. Pawson T., and Nash P. Assembly of cell regulatory systems through protein interaction domains. Science 300 (2003) 445-452
9. Manning B.D., and Cantley L.C. Hitting the target: Emerging technologies in the search for kinase substrates. Sci STKE (2002) E49
10. Raizer J.J. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74 (2005) 77-86
11. Eller J.L., Longo S.L., Hicklin D.J., and Canute G.W. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 51 (2002) 1005-1013
12. Eller J.L., Longo S.L., Kyle M.M., Bassano D., Hicklin D.J., and Canute G.W. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 56 (2005) 155-162
13. Raben D., Bianco C., Milas L., and Ang K.K. Targeted therapies and radiation for the treatment of head and neck cancer: Are we making progress?. Semin Radiat Oncol 14 (2004) 139-152
14. Raben D., Helfrich B., and Bunn Jr. P.A. Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys 59 (2004) 27-38
15. Raben D., Helfrich B.A., Chan D., Johnson G., and Bunn Jr. P.A. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29 (2002) 37-46
16. Watanabe K., Tachibana O., Sata K., Yonekawa Y., Kleihues P., and Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6 (1996) 217-223
17. Tohma Y., Gratas C., Van Meir E.G., et al. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 57 (1998) 239-245
18. Shinojima N., Tada K., Shiraishi S., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63 (2003) 6962-6970
19. Simmons M.L., Lamborn K.R., Takahashi M., et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61 (2001) 1122-1128
20. Kim E.S., Khuri F.R., and Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13 (2001) 506-513
21. Baumann M., and Krause M. Targeting the epidermal growth factor receptor in radiotherapy: Radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72 (2004) 257-266
22. Arteaga C.L. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 (2001) 32S-40S
23. Abdollahi A., Lipson K.E., Sckell A., et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63 (2003) 8890-8898
24. Abdollahi A., Lipson K.E., Han X., et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63 (2003) 3755-3763
25. Bischof M., Abdollahi A., Gong P., et al. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 60 (2004) 1220-1232
26. Pera M.F., Koberle B., and Masters J.R. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br J Cancer 71 (1995) 904-906
27. van Rijn J., Heimans J.J., van den Berg J., van der Valk P., and Slotman B.J. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47 (2000) 779-784
28. Reid J.M., Stevens D.C., Rubin J., and Ames M.M. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3 (1997) 2393-2398
29. Stevens M.F., Hickman J.A., Langdon S.P., et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47 (1987) 5846-5852
30. Liu L., Markowitz S., and Gerson S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56 (1996) 5375-5379
31. Hoi S.U., Espiritu O.D., Kelley P.Y., Klauber M.R., and Hatton J.D. The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth. J Neurosurg 82 (1995) 841-846
32. Hoi S.U., Espiritu O.D., Kelley P.Y., Klauber M.R., and Hatton J.D. The role of the epidermal growth factor receptor in human gliomas: II. The control of glial process extension and the expression of glial fibrillary acidic protein. J Neurosurg 82 (1995) 847-857
33. Schlegel J., Merdes A., Stumm G., et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56 (1994) 72-77
34. Wong A.J., Ruppert J.M., Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89 (1992) 2965-2969
35. Diedrich U., Lucius J., Baron E., Behnke J., Pabst B., and Zoll B. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 242 (1995) 683-688
36. Rainov N.G., Dobberstein K.U., Bahn H., et al. Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 35 (1997) 13-28
37. Etienne M.C., Formento J.L., Lebrun-Frenay C., et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4 (1998) 2383-2390
38. Jaros E., Perry R.H., Adam L., et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66 (1992) 373-385
39. Waha A., Baumann A., Wolf H.K., et al. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J Neurosurg 85 (1996) 634-641
40. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFR vIII gene. Cell Growth Differ 6 (1995) 1251-1259
41. Bigner S.H., Burger P.C., Wong A.J., et al. Gene amplification in malignant human gliomas: Clinical and histopathologic aspects. J Neuropathol Exp Neurol 47 (1988) 191-205
42. Hurtt M.R., Moossy J., Donovan-Peluso M., and Locker J. Amplification of epidermal growth factor receptor gene in gliomas: Histopathology and prognosis. J Neuropathol Exp Neurol 51 (1992) 84-90
43. Torp S.H., Helseth E., Dalen A., and Unsgaard G. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir 117 (1992) 182-186
44. Dorward N.L., Hawkins R.A., and Whittle I.R. Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma. Br J Neurosurg 7 (1993) 197-199
45. Hiesiger E.M., Hayes R.L., Pierz D.M., and Budzilovich G.N. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol 16 (1993) 93-104
46. Schober R., Bilzer T., Waha A., et al. The epidermal growth factor receptor in glioblastoma: Genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol 14 (1995) 169-174
47. Zhu A., Shaeffer J., Leslie S., Kolm P., and El Mahdi A.M. Epidermal growth factor receptor: An independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 34 (1996) 809-815
48. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
49. Korkolopoulou P., Christodoulou P., Kouzelis K., et al. MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75 (1997) 1269-1278
50. Newcomb E.W., Cohen H., Lee S.R., et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8 (1998) 655-667
51. Quan A.L., Barnett G.H., Lee S.Y., et al. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 63 (2005) 695-703
52. Chakravarti A., Delaney M.A., Noll E., et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7 (2001) 2387-2395
53. Schmidt M.C., Antweiler S., Urban N., et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61 (2002) 321-328
54. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97 (2000) 7503-7508
55. Riva P., Franceschi G., Arista A., et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: A six-year clinical experience. Cancer 80 (1997) 2733-2742
56. Hills D., Rowlinson-Busza G., and Gullick W.J. Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 63 (1995) 537-543
57. Dancey J.E., and Freidlin B. Targeting epidermal growth factor receptor-Are we missing the mark?. Lancet 362 (2003) 62-64
58. Combs S.E., Heeger S., Haselmann R., Edler L., Debus J., and Schulz-Ertner D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-phase I/II trial: Study protocol. BMC Cancer 6 (2006) 133